Therapy (HCV)

bDNA Predicts Interferon Response in Chronic HCV

Published in Hepatitis Weekly, May 20th, 1996

The measurement of serum hepatitis C virus RNA by the branched DNA probe assay may be a superior predictor of interferon response in patients with chronic hepatitis C.

A study from Japan suggested that the branched DNA probe assay (bDNA) is a better predictor of a complete response to interferon than measurement by competitive reverse transcription polymerase chain reaction (cRT-PCR), although the bDNA probe assay is less sensitive than cRT-PCR for detecting HCV RNA at lower concentrations.

The efficacy of interferon-alpha (IFN-(alpha)) in the treatment of patients with chronic hepatitis C is not fully known, and several reports have found that...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1996-05-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry